治疗前CT识别增殖型肝细胞癌:对经导管动脉化疗栓塞术后治疗结局的意义
这项回顾性多中心研究基于治疗前CT影像特征建立并外部验证了识别增殖型肝细胞癌的SMARS评分模型,训练队列AUC为0.83、验证队列AUC为0.80;按该模型预测为增殖型的患者接受cTACE后肿瘤缓解率、无进展生存期和总生存期均低于预测为非增殖型者。
要点
- SMARS评分纳入分叶状形态、马赛克结构、甲胎蛋白水平、环形动脉期高强化和卫星灶五项指标。
- 训练队列AUC 0.83、验证队列AUC 0.80,对增殖型肝细胞癌具有较好的识别效能。
- 预测为增殖型者cTACE后肿瘤缓解率48% vs 非增殖型71%,PFS 6.6个月 vs 12.4个月,OS 14.4个月 vs 38.7个月。
核心结论
- SMARS评分对识别增殖型肝细胞癌表现出良好效能;按SMARS评分预测为增殖型的患者cTACE后预后差于预测为非增殖型者。
研究设计与样本
- 回顾性多中心研究,纳入2013年8月至2020年12月间接受肝切除或cTACE的成人肝细胞癌患者共1194例(男性1021例,平均年龄54岁±12[SD],中位随访29.1个月);开发基于CT的预测模型并在接受肝切除的队列中进行外部验证。
关键影像表现/征象
- SMARS评分纳入分叶状形态、马赛克结构、甲胎蛋白水平、环形动脉期高强化和卫星灶。
- 预测为增殖型肝细胞癌者114例,预测为非增殖型者263例。
诊断标准与关键数值
- SMARS评分识别增殖型肝细胞癌的受试者工作特征曲线下面积:训练队列0.83,验证队列0.80。
- 预测增殖型组肿瘤缓解率48% vs 预测非增殖型组71%,P < .001。
- 预测增殖型组无进展生存期6.6个月 vs 预测非增殖型组12.4个月,P < .001。
- 预测增殖型组总生存期14.4个月 vs 预测非增殖型组38.7个月,P < .001。
临床应用与阅片要点
- 治疗前CT可依据分叶状形态、马赛克结构、环形动脉期高强化和卫星灶等征象联合甲胎蛋白水平计算SMARS评分,用于预测增殖型肝细胞癌。
- 按SMARS评分预测为增殖型的患者cTACE后肿瘤缓解率更低、PFS和OS更短。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Hepatocellular carcinomas (HCCs) can be divided into proliferative and nonproliferative types, which may have implications for outcomes after conventional transarterial chemoembolization (cTACE). Biopsy to identify proliferative HCC is not routinely performed before cTACE. Purpose To develop and validate a predictive model for identifying proliferative HCCs using CT imaging features and to compare therapeutic outcomes between predicted proliferative and nonproliferative HCCs after cTACE according to this model. Materials and Methods This retrospective multicenter study included adults with HCC who underwent liver resection or cTACE between August 2013 and December 2020. A CT-based predictive model for identifying proliferative HCCs was developed and externally validated in a cohort that underwent resection. Diagnostic performance was calculated for the model. Thereafter, patients in the cTACE cohort were stratified into groups with predicted proliferative or nonproliferative HCCs according to the model. The primary outcome was overall survival (OS), and the secondary outcomes were tumor response rate and progression-free survival (PFS). These were compared between the two groups with use of the χ2 test and the log-rank test. Results A total of 1194 patients (1021 men; mean age, 54 years ± 12 [SD]; median follow-up time, 29.1 months) were included. The predictive model, named the SMARS score, incorporated lobulated shape, mosaic architecture, α-fetoprotein levels, rim arterial phase hyperenhancement, and satellite lesions. The area under the receiver operating characteristic curve for the SMARS score was 0.83 for the training cohort and 0.80 for the validation cohort. According to the SMARS score, patients with predicted proliferative HCCs (n = 114) had lower tumor response rate (48% vs 71%; P < .001) and worse PFS (6.6 months vs 12.4 months; P < .001) and OS (14.4 months vs 38.7 months; P < .001) than those with nonproliferative HCCs (n = 263). Conclusion The predictive model demonstrated good performance for identifying proliferative HCCs. According to the SMARS score, patients with predicted proliferative HCCs have worse prognosis than those with predicted nonproliferative HCCs after cTACE. © RSNA, 2023 Supplemental material is available for this article.
引用
- Bao Y, Li JX, Zhou P, et al. Identifying Proliferative Hepatocellular Carcinoma at Pretreatment CT: Implications for Therapeutic Outcomes after Transarterial Chemoembolization. Radiology. 2023. PMID: 37642572. doi:10.1148/radiol.230457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。